Short Interest in Autolus Therapeutics plc (NASDAQ:AUTL) Rises By 8.7%

Autolus Therapeutics plc (NASDAQ:AUTL) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 9,110,000 shares, an increase of 8.7% from the January 15th total of 8,380,000 shares. Based on an average trading volume of 1,710,000 shares, the days-to-cover ratio is presently 5.3 days.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP raised its stake in Autolus Therapeutics by 4.6% during the fourth quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company’s stock valued at $59,562,000 after buying an additional 1,125,454 shares during the last quarter. FMR LLC raised its stake in Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after buying an additional 5,478,706 shares during the last quarter. Candriam S.C.A. purchased a new position in Autolus Therapeutics during the fourth quarter valued at $7,500,000. AXA S.A. purchased a new position in Autolus Therapeutics during the fourth quarter valued at $4,288,000. Finally, JPMorgan Chase & Co. raised its stake in Autolus Therapeutics by 145.3% during the third quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company’s stock valued at $4,663,000 after buying an additional 761,008 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on AUTL shares. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, January 13th. Finally, The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Autolus Therapeutics presently has an average rating of “Buy” and a consensus target price of $10.40.

Autolus Therapeutics Stock Up 5.2 %

NASDAQ AUTL opened at $2.04 on Monday. Autolus Therapeutics has a twelve month low of $1.87 and a twelve month high of $7.31. The firm has a market capitalization of $542.82 million, a PE ratio of -1.69 and a beta of 2.02. The stock’s 50 day moving average is $2.31 and its 200 day moving average is $3.26.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.